Off-the-shelf chimeric antigen receptor (CAR) product with broad applicability for malignant diseases

PRINCIPAL INVESTIGATOR:
Prof. Dr. Gabriele Pecher
Charité

SUMMARY

Cancer still remains the second leading cause of death worldwide. Tumors often do not respond to standard treatment and become essentially incurable. The team develops a novel advanced therapy medicinal product (ATMP) for the precision immunotherapy of both solid tumors and hematological diseases to generate an allogeneic, “off-the-shelf” CAR-modified therapeutic agent. The ATMP will be validated and preclinical testing will be accomplished.

PROJECT GOALS

• Generation of a novel allogeneic ATMP for anti-cancer therapy
• Preclinical development of the ATMP

LONG-TERM GOALS

• Perform phase I/II clinical trial
• License to Pharma or startup foundation